LODENAFIL

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H32N6O5S
Molecular Weight	504.602
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCC1=NN(C)C2=C1N=C(NC2=O)C3=C(OCC)C=CC(=C3)S(=O)(=O)N4CCN(CCO)CC4

InChI

InChIKey=NEYKRKVLEWKOBI-UHFFFAOYSA-N

InChI=1S/C23H32N6O5S/c1-4-6-18-20-21(27(3)26-18)23(31)25-22(24-20)17-15-16(7-8-19(17)34-5-2)35(32,33)29-11-9-28(10-12-29)13-14-30/h7-8,15,30H,4-6,9-14H2,1-3H3,(H,24,25,31)

HIDE SMILES / InChI

Molecular Formula	C23H32N6O5S
Molecular Weight	504.602
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18593576 | https://www.ncbi.nlm.nih.gov/pubmed/20214718

Lodenafil carbonate, a novel phosphodiesterase 5 inhibitor developed in Brazil. Lodenafil carbonate is a prodrug that is metabolized with formation of the active compound, lodenafil. Lodenafil carbonate participated in phase III clinical trial for erectile dysfunction and showed a satisfactory efficacy-safety profile.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
cGMP-specific 3',5'-cyclic phosphodiesterase 6 Target ID: O76074 Gene ID: 8654.0 Gene Symbol: PDE5A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/18593576	Inhibitor 8504

PubMed

Title	Date	PubMed
Lodenafil treatment in the monocrotaline model of pulmonary hypertension in rats.	2014-04-13	25210965
Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial.	2010-05	20214718
[Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, with and without alcohol consumption].	2010-02	20428608
Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum.	2008-09-04	18593576

Sample Use Guides

In Vivo Use Guide

lodenafil carbonate (LC) 40 mg or LC 80 mg and followed for 4 weeks

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:11:22 GMT 2025` Edited by `admin` on `Mon Mar 31 22:11:22 GMT 2025`
Record UNII	80X7B1F6NW
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

HYDROXYHOMOSILDENAFIL

Preferred Name

English

LODENAFIL

Common Name

English

Lodenafil [WHO-DD]

Common Name

English

7H-PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE, 5-(2-ETHOXY-5-((4-(2-HYDROXYETHYL)-1-PIPERAZINYL)SULFONYL)PHENYL)-1,6-DIHYDRO-1-METHYL-3-PROPYL-

Systematic Name

English

Classification Tree Code System Code

WIKIPEDIA

Designer-drugs-Lodenafil